Detalhe da pesquisa
1.
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction.
Cancer Cell Int
; 22(1): 286, 2022 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36123697
2.
TransCon IL-2 ß/γ: a novel long-acting prodrug with sustained release of an IL-2Rß/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
J Immunother Cancer
; 10(7)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35817480
3.
GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model.
Cancer Immunol Res
; 6(10): 1199-1211, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30154083